Literature DB >> 12969329

Antinuclear antibody testing in a regional immunopathology laboratory.

Peter J Roberts-Thomson1, Tony Nikoloutsopoulos, Sally Cox, Jennifer G Walker, Tom P Gordon.   

Abstract

A systematic review has been undertaken of antinuclear antibody testing over a 6-year period in a regional immunotherapy laboratory servicing a population of 400 000. Twenty-eight per cent of the 20 205 antinuclear antibody tests performed on a hyperexpressing Ro transfected cellular substrate were positive (titre >/= 1 : 80) with the most common immunofluorescent patterns being homogeneous (39%), speckled (20%), mixed (17%), nucleolar (8%), Ro (7%) and centromere (4%). Ro antibody as detected by immunofluorescence was strongly concordant with anti-Ro detected by counter immunoelectrophoresis precipitation; of 261 anti-Ro counter immunoelectrophoresis precipitation positive patients surveyed, only 15 were missed and 20 masked (with homogenous pattern) by immunofluorescence. Ro antibodies were found in patients with a variety of immune disorders, particularly connective tissue disorders, whilst a clinical survey of the anticentromere sera revealed that 67% were derived from patients with limited scleroderma. Extractable nuclear antibodies and their characterization was performed on 10 939 occasions with 12.9% being positive with anti-Ro constituting 30.2%, anti-Ro/La 25.7%, unidentified precipitin line 17.8%, anti-ribo nuclear protein 12.5%, respectively, with anti-Scl70, anti-Jo-1 and anti-Sm and various combinations making up the remainder. Unidentified precipitin lines were particular prominent in patients with connective tissue disorders. DNA quantification was performed on 12 068 occasions with 11% giving elevated values, the majority from patients with systemic lupus erythematosus. Of these positive sera 44% also demonstrated one or more extractable nuclear antibodies and 25% anticardiolipin antibodies. Regular participation in a Quality Assurance Program revealed accurate and consistent performance of antinuclear antibody testing. In conclusion antinuclear antibody detection and characterization for systemic immune disorders can provide the clinician with useful diagnostic and prognostic information; it is important that the laboratory results are relevant, timely, accurate and precise. Systematic reviews as demonstrated in this report, can provide such evidence.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12969329     DOI: 10.1046/j.1440-1711.2003.01181.x

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  8 in total

1.  Letter to the editor. Re: Specificity of anti-centromere antibodies for scleroderma.

Authors:  P Roberts-Thomson
Journal:  Rheumatol Int       Date:  2007-06-13       Impact factor: 2.631

2.  Antinuclear antibody positive autoimmune disorders in North India: an appraisal.

Authors:  Ranjana Walker Minz; Yashwant Kumar; Shashi Anand; Surjit Singh; Pradeep Bamberi; Subhash Verma; Shobha Shegal
Journal:  Rheumatol Int       Date:  2011-09-07       Impact factor: 2.631

3.  Comparison of the Prevalence of Antinuclear Antibody and Subserology in Urban and Rural Settings.

Authors:  Adrian Yong-Sing Lee; Leigh Murfett; Udayan Ray
Journal:  Arch Rheumatol       Date:  2016-07-27       Impact factor: 1.472

4.  Prevalence of antinuclear antibodies in healthy Lebanese subjects, 2008-2015: a cross-sectional study involving 10,814 subjects.

Authors:  Eddie Racoubian; Reem M Zubaid; Marwa A Shareef; Wassim Y Almawi
Journal:  Rheumatol Int       Date:  2016-07-13       Impact factor: 2.631

5.  Ductal epithelial expression of Ro52 correlates with inflammation in salivary glands of patients with primary Sjögren's syndrome.

Authors:  L A Aqrawi; M Kvarnström; K A Brokstad; R Jonsson; K Skarstein; M Wahren-Herlenius
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

Review 6.  Clinical Significance of Antinucleolar Antibodies: Biomarkers for Autoimmune Diseases, Malignancies, and others.

Authors:  Minoru Satoh; Angela Ceribelli; Tomoko Hasegawa; Shin Tanaka
Journal:  Clin Rev Allergy Immunol       Date:  2022-03-08       Impact factor: 10.817

7.  Breast cancer and systemic sclerosis: a clinical description of 21 patients in a population-based cohort study.

Authors:  Tim Y-T Lu; Catherine L Hill; Eliza K Pontifex; Peter J Roberts-Thomson
Journal:  Rheumatol Int       Date:  2008-02-16       Impact factor: 2.631

Review 8.  Autoantibodies Associated With Connective Tissue Diseases: What Meaning for Clinicians?

Authors:  Kevin Didier; Loïs Bolko; Delphine Giusti; Segolene Toquet; Ailsa Robbins; Frank Antonicelli; Amelie Servettaz
Journal:  Front Immunol       Date:  2018-03-26       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.